Skip to main content

Table 2 Clinical performance of cervical cancer screening methods/tools for detecting CIN2+

From: Prevention of cervical cancer in HIV-seropositive women from developing countries through cervical cancer screening: a systematic review

Author, year of publication Screening method/tool HIV-infected HIV-negative
Sensitivity Specificity PPV NPV Sensitivity Specificity PPV NPV
Bansil et al., 2015 VIA 77.1 (59.9–89.6) 47.3 (40.8–53.8) 17.8 (12.0–24.8) 93.3 (87.3–97.1) 93.8 (69.8–99.8) 60.5 (57.3–63.7) 3.9 (2.2–6.4) 99.8(99.0–100.0)
Chung et al., 2013 VIA 62.7 (53.4–71.2) 65.9 (60.7–70.7) 37.1 (30.5–44.2) 84.6 (79.8–88.5)     
Dartell et al., 2014 VIA 50.0 (31.5–68.5) 90.5 (87.2–93.8) 32.6 95.2 22.9 (14.5–31.3) 97.2 (96.7–97.8) 21.6 97.5
Huchko et al., 2015 VIA 84.0 (64.0–95.5) 78.6 (73.5–83.1) 24.7 (16.0–35.3) 98.3 (95.8–99.5)     
Joshi et al., 2013 VIA 83.6 (71.2–92.2) 88.8 (86.7–90.6) 27.7 (21.1–35.2) 99.1 (98.2–99.6)     
Kuhn et al., 2010 VIA 63.9 (46.2–79.2) 73.5 (67.4–78.8) 27.5 (17.8–37.3) 90.9 (85.8–96.0) 47.8 (35.7–60.2) 80.3 (78.2–82.2) 9.6 (6.5–12.7) 96.7 (95.6–97.8)
Mabeya et al., 2012 VIA 69.6 51.0 38.6 79.1     
Sahasrabuddhe et al., 2012 VIA 80.0 (66.3–90.0) 82.6 (77.4–87.1) 47.6 (36.6–58.9) 95.4 (91.8–97.8)     
Akinwuntan et al., 2008 VIA 76.0 (52.0–91.0) 83.0 (77.0–88.0) 34.0 (21.0–49.0) 97.0 (92.0–99.0)     
Firnhaber et al., 2016 VIA 65.4 (59.7–71.1) 68.5 (65.3–71.7)       
Chibwesha et al., 2016 VIA 48.0 (30.0–67.0) 92.0 (86.0–95.0) 52.0 (33.0–71.0) 91.0 (85.0–95.0)     
Huchko et al., 2015 VILI 84.2 (68.7–94.0) 76.4 (71.2–81.3) 31.7 (22.8–41.7) 97.4 (94.4–99.0)     
Joshi et al., 2013 VILI 89.1 (77.8–95.9) 89.3 (87.3–91.1) 30.1 (23.1–37.7) 99.4 (98.6–99.8)     
Chibwesha et al., 2016 DC 59.0 (41.0–76.0) 88.0 (82.0–93.0) 49.0 (32.0–65.0) 92.0 (87.0–96.0)     
Bateman et al., 2014 DC 84.0 (72.0–91.0) 58.0 (52.0–64.0) 33.0 (26.0–41.0) 93.0 (88.0–96.0)     
Joshi et al., 2013 Pap smear 63.3 (48.3–76.6) 94.5 (92.9–95.8) 35.2 (25.3–46.1) 98.2 (97.2–98.9)     
Chung et al., 2013 Pap smear 71.8 (62.8–79.4) 97.1 (94.7–98.4) 88.8 (80.5–93.8) 91.5 (88.2–93.9)     
Mabeya et al., 2013 Pap smear 52.5 66.3 39.7 76.8     
Sahasrabuddhe et al., 2012 Pap smear 60.5 (44.4–75.0) 64.6 (57.9–70.8) 24.8 (16.9–34.1) 89.4 (83.6–93.7)     
Akinwuntan et al., 2008 Pap smear 57.0 (34.0–77.0) 95.0 (90.0–97.0) 55.0 (33.0–75.0) 95.0 (91.0–98.0)     
Firnhaber et al., 2013 Pap smear 75.8 (70.8–80.8) 83.4 (80.9–85.9)       
Bateman et al., 2014 Pap smear 61.0 (48.0–72.0) 58.0 (52.0–64.0) 27.0 (20.0–35.0) 86.0 (79.0–90.0)     
Michelow et al., 2016 Cellslide® automated liquid-based cytology 76.0 (64.8–85.1) 91.0 (87.0–94.2) 70.4 (59.2–80.0) 93.1 (89.4–95.9)     
Bansil et al., 2015 Vaginal careHPV 80.0 (63.1–91.6) 59.9 (53.4–66.2) 22.8 (15.7–31.2) 95.3 (90.6–98.1) 75.0 (47.6–92.7) 81.9 (79.3–84.4) 6.7 (3.5–11.4) 99.5 (98.7–99.9)
Bansil et al., 2015 Cervical careHPV 94.3 (80.8–99.3) 62.4 (55.9–68.6) 27.0 (19.4–35.8) 98.7 (95.3–99.8) 81.3 (54.4–96.0) 80.9 (78.2–83.3) 6.8 (3.7–11.4) 99.6 (98.8–99.9)
Obiri-Yeboah et al., 2017 CareHPV 87.5 (47.3–99.7) 52.1 (44.7–59.5) 7.2 (3.0–14.3) 99.0 (94.5–100.0)     
Segondy et al., 2016 [36] CareHPV 93.3 (83.8–98.2) 57.9 (54.5–61.2)       
Chung et al., 2013 HPV DNA test 83.6 (75.6–89.4) 55.7 (50.4–60.9) 37.7 (31.9–43.9) 91.4 (86.8–94.5)     
Dartell et al., 2014 HR HPV 100.0 58.2 (52.6.63.7) 17.9 100.0 92.7 (87.5–97.9) 85.3 (84.0–86.6) 17.2 99.7
Joshi et al., 2013 HC2 test 94.6 (84.9–98.9) 77.4 (74.8–79.9) 17.8 (13.6–22.6) 99.6 (99.0–99.9)     
Ngou et al., 2015 HC2 88.8 55.2 24.7 96.7     
Ngou et al., 2015 INNO-LiPA 92.5 35.1 19.1 96.6     
Obiri-Yeboah et al., 2017 Anyplex II HPV 28 87.5 (47.3–99.7) 38.8 (31.8–46.2) 5.7 (2.3–11.5) 98.6 (92.7–100.0)     
Firnhaber et al., 2016 HC2 91.9 (88.5–95.3) 51.4 (48.0–54.8)       
Chibwesha et al., 2016 Xpert HPV 88.0 (71.0–97.0) 60.0 (52.0–86.0) 30.0 (21.0–40.0) 96.0 (90.0–99.0)     
Chibwesha et al., 2016 OncoE6 31.0 (16.0–50.0) 99.0 (97.0–100) 91.0 (59–100) 88.0 (83.0–93.0)     
Segondy et al., 2016 INNO-LiPA 96.7 (88.5–99.6) 32.0 (29.0–35.2)       
Kuhn et al., 2010 HPV DNA 94.4 (81.3–99.3) 64.4 (58.0–70.3) 29.9 (21.3–38.6) 97.2 (87.0–99.4) 87.0 (76.7–93.9) 87.0 (85.2–88.6) 22.7(17.6–27.9) 99.0 (97.9–99.5)
Wu et al., 2016 P16INK4a cutoff level = 9 U/mL (%) 89.0 22.9 13.6 93.8     
Chung et al., 2013 VIA + HPV test 58.2 (48.8–67.0) 83.7 (79.4–87.2) 53.3 (44.4–62.0) 86.2 (82.1–89.5)     
Chung et al., 2013 VIA + Pap smear 50.9 (41.7–60.1) 99.1 (97.5–99.7) 94.9 (86.1–98.3) 86.3 (82.5–89.3)     
Chung et al., 2013 HPV + Pap smear 62.7 (53.4–71.2) 98.5 (96.6–99.4) 93.2 (85.1–97.1) 89.2 (85.7–91.9)     
Joshi et al., 2013 VIA and VILI 81.8 (69.1–90.9) 93.2 (91.5–94.6)       
Joshi et al., 2013 HC2 and VIA 80.0 (67.0–89.6) 96.0 (94.6–97.1)       
Joshi et al., 2013 HC2 and VILI 83.6 (71.2–92.2) 96.9 (95.7–97.9)       
Joshi et al., 2013 HC2 and VIA/VILI 85.5 (73.3–93.5) 95.3 (93.9–96.5)       
Joshi et al., 2013 VIA and cytology 57.1 (42.2–71.2) 98.8 (98.0–99.4)       
Joshi et al., 2013 VILI and cytology 55.1 (40.2–69.3) 99.6 (99.0–99.9)       
Joshi et al., 2013 HC2 and cytology 63.3 (48.3–76.6) 96.6 (95.3–97.6)       
  1. VIA visual inspection with acetic acid, VILI visual inspection with Lugol’s iodine, DC digital cervicography, HR-HPV high-risk human papillomavirus, HC2 Hybrid Capture-2, PPV positive predictive value, NPV negative predictive value